Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eledon Pharmaceuticals, Inc.

3.44
+0.590020.70%
Post-market: 3.42-0.0200-0.58%19:59 EDT
Volume:5.64M
Turnover:19.23M
Market Cap:205.99M
PE:16.22
High:3.70
Open:2.91
Low:2.87
Close:2.85
52wk High:5.54
52wk Low:2.32
Shares:59.88M
Float Shares:46.04M
Volume Ratio:4.70
T/O Rate:12.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2121
EPS(LYR):-0.7454
ROE:30.03%
ROA:-41.40%
PB:1.94
PE(LYR):-4.62

Loading ...

Eledon Pharmaceuticals to Present Phase 2 BESTOW Trial Results of Tegoprubart for Kidney Transplant Rejection Prevention at ASN Kidney Week 2025

Reuters
·
Oct 17

Eledon Pharmaceuticals to Present on Anti-CD154 Pathway Blockade at International Xenotransplantation Association Congress

Reuters
·
Sep 25

Eledon Pharmaceuticals Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 02

Eledon Pharmaceuticals Inc. to Participate in Cantor Global Healthcare Conference 2025

Reuters
·
Aug 29

Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 19

Eledon Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
Aug 16

Eledon Pharmaceuticals Inc - Management Concludes Financial Statements Materially Misstated - SEC Filing

THOMSON REUTERS
·
Aug 15

Eledon Pharmaceuticals Inc - Errors Did Not Impact Eledon's Cash, Liquidity, or Operations - SEC Filing

THOMSON REUTERS
·
Aug 15

Eledon Pharmaceuticals Inc. Files Amendment to 10-K Annual Report

Reuters
·
Aug 15

Eledon Pharma Q2 EPS $(0.13) Beats $(0.24) Estimate

Benzinga
·
Aug 15

Eledon Pharmaceuticals Reports Q2 2025 Net Loss of $11.2M, EPS Improves to $0.13 from $0.92 in 2024

Reuters
·
Aug 15

Eledon Pharmaceuticals Q2 Operating Expenses USD 24.733 Million

THOMSON REUTERS
·
Aug 15

Eledon Pharmaceuticals Inc - Expects Cash and Other Investments to Fund Operations to End of 2026

THOMSON REUTERS
·
Aug 15

Eledon Pharmaceuticals Inc - Tegoprubart Well Tolerated With No Death or Graft Loss

THOMSON REUTERS
·
Aug 07

Eledon Pharmaceuticals Inc - Data Shows 12-Month Egfr of 68 Ml/Min Post-Transplant

THOMSON REUTERS
·
Aug 07

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

GlobeNewswire
·
Aug 07

Eledon Pharmaceuticals Announces Conference Call to Discuss Updated Phase 1b Trial Data for Tegoprubart in Kidney Transplantation at World Transplant Congress 2025

Reuters
·
Jul 31

Eledon Pharmaceuticals Initiated at Buy by Craig-Hallum

Dow Jones
·
Jul 26

Eledon Pharmaceuticals Announces Updated Data from Phase 1b Trial of Tegoprubart for Kidney Transplant Rejection Prevention at World Transplant Congress 2025

Reuters
·
Jul 18

Eledon Pharmaceuticals, Sernova Collaborate to Test Tegoprubart in Type 1 Diabetes

MT Newswires Live
·
Jul 09